NCT05020236: Phase 3-MagnetisMM-5: Elranatamab (PF-06863135) Vs & Elranatamab/Dara VS Dara/Pom/Dex
NCT05060627: Phase 1/2: Belantamab Mafodotin + Kd RRMM Multiple Myeloma, Refractory to Lenalidomide
NCT05139225: Phase 1: A Study of TTI-621 and TTI-622 in Combination With Daratumumab RRMM
NCT05090566: Phase 2 MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) + Anti-Cancer Tx RRMM
NCT04855136 : Phase 1/2 - Safety and Efficacy of bb2121 (Ide-cel) Combinations in MM (KarMMa-7)
NCT05137054: Phase 1: REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Tx RRMM
NCT05121103: Phase 1: A Study in Subjects With Relapsed/Refractory Multiple Myeloma and RR DLBCL
NCT05014412: Phase 1/2: Elranatamab in MM That Has Come Back or Has not responded - MagnetisMM-9
NCT04764942: Phase 1/2: Selinexor, Pom, Dex +/- Carfilzomib RRMM Multiple Myeloma, The SCOPE Trial
NCT04998747: Phase 1: A Study of Subcutaneous (SC) AMG 701 in RRMM Myeloma - (ProxiMMity-1)
NCT04910568: Phase 1b - Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04973605: Phase 1/2: BGB-11417 in Monotherapy and With Carfilzomib-dex in RRMM and t(11;14)
NCT04975997: Phase 3: IberDd Versus DVd in Participants With Relapsed Refractory Myeloma - EXCALIBER
NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants RRMM
NCT04960579: Phase 1: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Multiple Myeloma
NCT04942067: Phase 1/2: APG-2575 in Combination With Novel Therapeutic Regimens in RRMM Myeloma
NCT04843579: Phase 2: Selinexor in Combination With Clarithromycin, Pom & Dex RRMM - ClaSPd
NCT04879043: Phase 1/2: Study to Assess Safety of HDP-101 in Patients With RRMM
Expanded Access Protocol for Receiving Idecabtagene Vicleucel That is Nonconforming for commercial